Our Semaglutide 1.25 mg/mL Sublingual Suspension is a meticulously crafted liquid formulation, specifically designed for sublingual administration. This advanced delivery system is delivered via oral syringe, which allows for precise dosing and ease of use. The formulation is particularly suitable for patients who require smaller doses or for those who may face challenges swallowing traditional solid dosage forms, such as tablets or capsules, including pediatric patients.

The base of our formulation, SubMagna™ SL HMW, is a cutting-edge, anhydrous, self-emulsifying, and permeation-enhancing sublingual suspension vehicle. It is engineered to deliver a broad spectrum of drugs, including those with high molecular weights (HMWs). Upon administration under the tongue, SubMagna™ SL HMW interacts with saliva to form an emulsion, which significantly enhances the solubility and dispersibility of the active pharmaceutical ingredient (API), in this case, Semaglutide. This interaction not only improves the absorption of the medication but also ensures a more consistent and reliable dosing experience.

The unique mucoadhesive properties of SubMagna™ SL HMW extend the contact time between the medication and the mucosal tissues, facilitating greater absorption of the API. This is particularly beneficial for molecules with high molecular weights, which typically face challenges in penetrating mucosal barriers. Additionally, the anhydrous nature of the formulation may contribute to extended beyond-use-dates (BUDs), offering potential advantages in terms of product stability and shelf life.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is used in the treatment of type 2 diabetes mellitus. It works by enhancing the secretion of insulin, suppressing the release of glucagon, and slowing gastric emptying, thereby improving glycemic control. By utilizing the sublingual route of administration, our formulation aims to bypass the gastrointestinal tract, which can often present obstacles to the bioavailability of the API due to degradation or altered absorption. This can be particularly advantageous for patients with gastrointestinal issues or for those who are on medications that may interfere with the absorption of oral medications.

For patients and prescribers considering this innovative Semaglutide 1.25 mg/mL Sublingual Suspension, it represents a promising alternative to conventional oral or injectable forms, offering the potential for improved patient compliance and therapeutic outcomes. If you have any questions or require further information about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of expert compounding pharmacists is dedicated to providing support and guidance to ensure the best possible care for our patients.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the management of type 2 diabetes mellitus to improve glycemic control in conjunction with diet and exercise. It functions by enhancing insulin secretion, suppressing glucagon secretion, and slowing gastric emptying. When considering drug interactions for semaglutide, it is important to note that the sublingual route of administration may alter the interaction profile compared to the more commonly used subcutaneous route.

One significant interaction to be aware of is with oral medications that require threshold concentrations for efficacy. Since semaglutide can slow gastric emptying, it may impact the absorption of concomitantly administered oral drugs. Patients should be advised to take oral medications that are affected by slower gastric emptying at least 1 hour before or 4 hours after semaglutide administration. Examples include oral contraceptives or antibiotics like tetracycline and doxycycline.

Additionally, semaglutide may increase the risk of hypoglycemia when used in combination with insulin or insulin secretagogues such as sulfonylureas. Patients should be monitored closely for signs of hypoglycemia, and dose adjustments of the concomitant insulin or sulfonylurea may be necessary.

Patients on antidiabetic agents, such as thiazolidinediones or insulin, may also experience an additive effect on blood glucose control when used with semaglutide. This could lead to an increased risk of hypoglycemia, and careful monitoring of blood glucose is recommended when initiating or adjusting the dose of semaglutide in these patients.

It is also important to consider the potential for semaglutide to interact with drugs that affect gastrointestinal motility, such as prokinetic agents or opioids. The effects of these drugs on gastric emptying may be altered when used concurrently with semaglutide, and patients should be monitored for gastrointestinal symptoms.

Warfarin or other oral anticoagulants may interact with semaglutide, potentially leading to changes in their anticoagulant effect. Patients on these medications should have their international normalized ratio (INR) monitored more frequently when starting or adjusting the dose of semaglutide.

Given the unique formulation of SubMagna™ SL HMW, it is also important to consider the excipients within the base and their potential to interact with other medications. The self-emulsifying and permeation-enhancing properties of the base may affect the absorption of concomitant sublingually administered drugs. Therefore, caution should be exercised when other sublingual medications are prescribed concurrently with semaglutide in the SubMagna™ SL HMW base.

Patients and prescribers should be aware that this is not an exhaustive list of all potential drug interactions. It is essential to review all medications, including over-the-counter drugs and herbal supplements, that a patient is taking to identify any other possible interactions. If you have any questions or require further information regarding drug interactions with semaglutide sublingual suspension, please reach out to us at Bayview Pharmacy for personalized advice and support.

\*Note: The beyond-use-date (BUD) will be determined based on the specific formulation and should be strictly adhered to, ensuring the medication's efficacy and safety.

The Semaglutide 1.25 mg/mL Sublingual Suspension is a cutting-edge formulation designed to treat conditions such as type 2 diabetes by utilizing the sublingual route of administration. This method involves placing the medication under the tongue, where it is rapidly absorbed into the bloodstream. The suspension is dispensed via oral syringe, allowing for precise dosing and ease of use, particularly for patients who may have difficulty swallowing traditional tablets or capsules.

Our formulation leverages the innovative SubMagna™ SL HMW base, which is specifically engineered to deliver drugs of varying molecular weights, including high molecular weight substances like semaglutide. The base is anhydrous, meaning it contains no water, which contributes to its stability and extends the beyond-use-date of the formulation. Upon administration, the SubMagna base interacts with saliva to form an emulsion, which enhances the solubility and dispersibility of the active pharmaceutical ingredient (API), in this case, semaglutide.

The permeation-enhancing properties of the SubMagna base are crucial for the sublingual delivery of semaglutide. These properties facilitate the penetration of the medication through the mucosal tissues under the tongue, ensuring that the drug is efficiently absorbed into the systemic circulation. Additionally, the unique mucoadhesive characteristics of the base prolong the contact time between the medication and the mucosal surface, potentially increasing the absorption of semaglutide and improving its therapeutic effect.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which works by mimicking the action of the GLP-1 hormone. It stimulates insulin secretion, suppresses glucagon secretion, and slows gastric emptying, all of which contribute to lowering blood glucose levels. By using the sublingual route, the Semaglutide Sublingual Suspension can bypass the gastrointestinal tract, where factors such as pH and digestive enzymes can affect the bioavailability of the medication. This direct absorption into the bloodstream can lead to a more predictable pharmacokinetic profile and may reduce gastrointestinal side effects associated with GLP-1 receptor agonists.

For patients and prescribers considering this formulation, it is important to note that the sublingual administration of semaglutide offers a convenient and potentially more tolerable alternative to injectable forms of the medication. The precise dosing provided by the oral syringe ensures that patients receive the correct amount of medication, which is essential for managing type 2 diabetes. If you have any questions or require further information about the Semaglutide 1.25 mg/mL Sublingual Suspension, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide the support and guidance you need.

While the primary indication for Semaglutide 1.25 mg/mL Sublingual Suspension is the management of type 2 diabetes mellitus, the unique properties of the SubMagna™ SL HMW base may allow for other potential uses. The sublingual route of administration bypasses the gastrointestinal tract, which can be particularly beneficial for patients with gastrointestinal disorders that affect the absorption of oral medications. Additionally, this route can be advantageous for drugs that undergo significant first-pass metabolism, potentially allowing for a reduction in dose and associated side effects.

Given the permeation-enhancing and mucoadhesive characteristics of the SubMagna™ SL HMW base, this formulation could be explored for use with other high molecular weight drugs that require enhanced absorption into the systemic circulation. This might include certain hormones, peptides, or biologic medications that typically have limited oral bioavailability. The sublingual suspension could also be of interest in the field of pain management, where rapid onset of action is often desired, or in situations where swallowing pills is difficult or contraindicated.

Moreover, the anhydrous nature of the SubMagna™ SL HMW base may extend the beyond-use-dates of the formulation, which is particularly useful for drugs that are sensitive to degradation in aqueous environments. This could be beneficial for medications used in treating chronic conditions that require long-term, stable formulations.

It is important to note that any new uses of Semaglutide 1.25 mg/mL Sublingual Suspension would require thorough investigation and approval by regulatory authorities. Prescribers and patients interested in exploring the potential of this formulation for other indications should engage in a collaborative discussion to weigh the benefits and risks. If you have any questions or require further information about the potential applications of this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is committed to providing comprehensive support and guidance to ensure the safe use of our compounded medications.